Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.

ABSTRACT:

Background

The evidence base of tisagenlecleucel is uncertain.

Objective

To evaluate the cost-effectiveness of tisagenlecleucel. To conduct expected value of perfect information (EVPI) and partial EVPI (EVPPI) analyses.

Study design

A three-state partitioned survival model. A short-term decision tree partitioned patients in the tisagenlecleucel arm according to infusion status. Survival was extrapolated to 5 years; general population mortality with a standardised mortality ratio was then applied. EVPI and EVPPI were scaled up to population according to the incidence of the decision.

Setting

Irish healthcare payer.

Participants

Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Interventions

Tisagenlecleucel versus Salvage

SUBMITTER: Carey N 

PROVIDER: S-EPMC9858398 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature